DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Seeking Alpha
CEO Dietrich Pauls highlighted ongoing progress for DM199, the lead product candidate, emphasizing its role as "a recombinant form of the naturally occurring human tissue KLK1 protein." Pauls noted favorable interim results in Quick Insights DM199 showed favorable interim results and strong safety profile in preeclampsia, with expansion cohort completion expected in first half of 2026. The ReMEDy2 stroke trial is progressing more slowly due to enrollment issues, with interim analysis anticipated in the second half of 2026. DiaMedica reported $55.3 million in cash and investments after a July private placement, projecting this will fund planned studies and operations into the second half of 2027 despite rising R&D and administrative expenses. Major risks include slower than projected stroke trial enrollment, protocol amendments, and increased expenses, although the company is implementing mitigation strategies and adjusting forecasts based on actual enrollment rates. More Tr
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business HighlightsBusiness Wire
- DiaMedica Therapeutics to Participate in the Jefferies Global Healthcare Conference in London [Yahoo! Finance]Yahoo! Finance
DMAC
Earnings
- 11/12/25 - Miss
DMAC
Sec Filings
- 11/25/25 - Form 4
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- DMAC's page on the SEC website